Cancer Research UK’s technology development arm, and Teva Pharmaceuticals have signed a multi-project alliance agreement to research and develop first-in-class cancer drugs that modulate DNA damage and repair response (DDR) processes in cancer cells. The US FDA also approved two of Teva’s cancer medications – for secondary cancers and for non-Hodgkin lymphoma.
http://www.globes.co.il/serveen/globes/docview.asp?did=1000879710&fid=1725
http://www.globes.co.il/serveen/globes/docview.asp?did=1000880109&fid=1725
http://www.globes.co.il/serveen/globes/docview.asp?did=1000880200&fid=1725